开发一种高强度的神经-3受体抑制剂:设计,合成和评估
Shengmin Ji1, Hui Wang2, Hengwei Xu1
1School of Pharmacy, Key Laboratory of Molecular Pharmacology and Drug Evaluation (Yantai University), Ministry of Education, Collaborative Innovation Center of Advanced Drug Delivery System and Biotech Drugs in Universities of Shandong, Yantai University, Yantai 264005, China.
ACS medicinal chemistry letters
|July 16, 2025
概括
新的伊米达-皮佩拉衍生物被合成,以向神经素-3受体 (NK3R). 化合物22i显示出强大的NK3R抑制和治疗热的潜力.
科学领域:
- 药用化学 医学化学
- 药理学 药理学是指药理学的学科.
背景情况:
- 神经基因-3受体 (NK3R) 是管理热等疾病的关键标.
- 目前的NK3R抗剂选择有限,突出显示了对新治疗剂的需求.
研究的目的:
- 设计和合成新的伊米达-皮佩拉衍生物作为潜在的NK3R抗剂.
- 评估这些新型化合物的疗效和药理动力学特性.
主要方法:
- 合理的药物设计和化学合成伊米达-皮佩拉衍生物.
- 分子对接研究来预测目标结合.
- 在体外评估NK3R抑制活性和膜透性.
- 在体内研究,以评估口服生物利用率和疗效 (氨化激素抑制).
主要成果:
- 一系列新的伊米达-皮佩拉衍生物 (化合物13a-13l,17a-17f,22a-22i) 已成功合成.
- 化合物22i显示出强大的NK3R结合和抑制活性,通过分子对接验证.
- 化合物22i表现出良好的膜透性和高口服生物利用性.
- 在体内研究证实,口服22i有效抑制了黄素激素水平.
结论:
- 合成的伊米达-皮佩拉衍生物是NK3R对抗的有希望的候选物.
- 化合物22i显示出作为神经基因因B信号介导的条件的治疗剂的显著潜力,需要进一步开发.
相关概念视频
Chemotherapy-Induced Nausea and Vomiting: Neurokinin-1 Receptor Antagonists
265
Neurokinin 1 (NK1) receptors are distributed across the GI tract, vagal afferents, and key CNS regions including the central vomiting center and chemoreceptor trigger zone (CTZ) Chemotherapy agents stimulate enterochromaffin cells in the gastrointestinal (GI) tract to release large amounts of substance P (SP). SP is a neuropeptide released by specific sensory nerves in response to many different stressors, including those in the GI mucosa affected by chemotherapy. SP binds and activates...
265
Drug Discovery: Overview
8.8K
Drug discovery is a multifaceted process involving extensive screening, testing, and optimization of lead compounds to identify potential new drugs for therapeutic use. It combines several approaches, including screening large numbers of natural products, chemical modification of known active molecules, identification of new drug targets, and rational design based on biological mechanisms and drug-receptor structure. These approaches are carried out in both academic research laboratories and...
8.8K
Structure-Activity Relationships and Drug Design
1.1K
Drug design is a dynamic field that involves discovering and developing new medications based on specific biological targets. This process heavily relies on structure-activity relationships (SAR) and quantitative structure-activity relationships (QSAR) to guide the design and optimization of efficient drugs.
SAR studies the intricate relationship between a drug's chemical structure and biological activity. It focuses on understanding how modifications to a drug's structure can influence...
SAR studies the intricate relationship between a drug's chemical structure and biological activity. It focuses on understanding how modifications to a drug's structure can influence...
1.1K

![Technical Aspect of the Automated Synthesis and Real-Time Kinetic Evaluation of [11C]SNAP-7941](/_next/image?url=https%3A%2F%2Fcloudfront.jove.com%2FCDNSource%2Fteasers%2F59557.jpg&w=3840&q=50)
